{"doi":"10.1001/jamainternmed.2015.7248","title":"Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels","abstract":null,"journal":"JAMA Internal Medicine","year":2016,"id":29059,"datarank":4.342864649174099,"base_score":3.8501476017100584,"endowment":3.8501476017100584,"self_citation_contribution":0.5775221402565088,"citation_network_contribution":3.76534250891759,"self_endowment_contribution":0.5775221402565088,"citer_contribution":3.76534250891759,"corpus_percentile":null,"corpus_rank":null,"citation_count":46,"citer_count":46,"citers_with_citation_signal":42,"citers_with_endowment":42,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":161117,"name":"Dhruv S. Kazi","orcid":null,"position":1,"is_corresponding":false},{"id":161118,"name":"Steven D. Pearson","orcid":null,"position":2,"is_corresponding":false},{"id":161116,"name":"Jeffrey A. Tice","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":3.8501476017100584,"endowment":3.8501476017100584,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26662572","pmcid":null,"openalex_id":"https://openalex.org/W2200107209","authors":[],"funders":[],"total_grants":0,"fwci":10.3631,"citation_percentile":0.98778024,"influential_citations":0,"citation_trend":[{"year":2016,"count":18},{"year":2017,"count":11},{"year":2018,"count":7},{"year":2019,"count":4},{"year":2020,"count":1},{"year":2021,"count":1},{"year":2024,"count":1},{"year":2025,"count":2}],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2474398","host_type":"publisher"},{"url":"https://doi.org/10.1001/jamainternmed.2015.7248","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/26662572","host_type":"repository"}],"fields_of_study":["Lipoproteins and Cardiovascular Health","Health Systems, Economic Evaluations, Quality of Life","Pharmaceutical Economics and Policy","Medicine","Antibodies, Monoclonal","Antibodies, Monoclonal, Humanized","Anticholesteremic Agents","Cardiovascular Diseases","Cholesterol, LDL","Cost-Benefit Analysis","Humans","Hypercholesterolemia","Proprotein Convertase 9","Proprotein Convertases","Serine Endopeptidases","Treatment Outcome"],"mesh_terms":["Proprotein Convertase 9","Antibodies, Monoclonal","Anticholesteremic Agents","Cardiovascular Diseases","Cost-Benefit Analysis","Humans","Hypercholesterolemia","Cholesterol, LDL","Serine Endopeptidases","Treatment Outcome","Proprotein Convertases","Antibodies, Monoclonal, Humanized"],"keywords":["Kexin","Proprotein convertase","Subtilisin","PCSK9","Medicine","Cholesterol","Evolocumab","Pharmacology","Internal medicine","Biochemistry","LDL receptor","Enzyme","Lipoprotein"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Partnerships for the goals"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-08T22:35:10.914679Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}